Circulating Sex Steroids during Pregnancy and Maternal Risk of Non-epithelial Ovarian Cancer


Abstract

Background: Sex steroid hormones have been proposed to play a role in the development of non-epithelial ovarian cancers (NEOC) but so far no direct epidemiologic data are available.

Methods: A case–control study was nested within the Finnish Maternity Cohort, the world’s largest biorepository of serum specimens from pregnant women. Study subjects were selected among women who donated a blood sample during a singleton pregnancy that led to the birth of their last child preceding diagnosis of NEOC. Case subjects were 41 women with sex cord stromal tumors (SCST) and 21 with germ cell tumors (GCT). Three controls, matching the index case for age, parity at the index pregnancy, and date at blood donation were selected (n = 171). OR and 95% CI associated with concentrations of testosterone, androstenedione, 17-OH-progesterone, progesterone, estradiol, and sex hormone–binding globulin (SHBG) were estimated through conditional logistic regression.

Results: For SCST, doubling of testosterone, androstenedione, and 17-OH-progesterone concentrations were associated with about 2-fold higher risk of SCST [ORs and 95% CI of 2.16 (1.25–3.74), 2.16 (1.20–3.87), and 2.62 (1.27–5.38), respectively]. These associations remained largely unchanged after excluding women within 2-, 4-, or 6-year lag time between blood donation and cancer diagnosis. Sex steroid hormones concentrations were not related to maternal risk of GCT.

Conclusions: This is the first prospective study providing initial evidence that elevated androgens play a role in the pathogenesis of SCST.

Impact: Our study may note a particular need for larger confirmatory investigations on sex steroids and NEOC.

Introduction

Non-epithelial ovarian cancers (NEOC) account for approximately 10% of all ovarian tumors and about 7% of the invasive ones (1). They are divided into 2 major distinct subtypes, sex cord-stromal tumors (SCST) and germ cell tumors (GCT; refs. 1–3). SCST occur in women of all ages but increase in frequency during the fourth and fifth decades of age and have a median age at diagnosis of 52 years (4–6). In contrast, GCT occur predominantly in young women with the peak incidence around the age of 18 and are rarely observed after age 30 years (7). The incidence rates of the 2 subtypes of NEOC also differ by race: SCST are twice as frequent in women of European and American background as in women from Asian descent (4), whereas GCT are more frequent in Asian women (8, 9).

Because of the low incidence of NEOC, very few studies have investigated risk factors for their development. So far, only 6 studies, 5 of which included between 10 and 72 cases of SCST or GCT, have reported on the association of these tumors with traditional reproductive risk factors, such as parity, oral contraceptive use, ages at the first and last births, and time since last birth (1, 10–14). Although the results from these studies are not entirely consistent, parous women appear to be at reduced risk of both SCST and GCT (1, 10, 12), but, there is some indication that the effect of other reproductive factors (1, 11, 12, 15), particularly age at last birth (11, 12), may differ in the 2 subtypes. It has also been suggested that exposure to high...
estrogens in utero may be associated with NEOC in the offspring (16, 17) and, possibly, also in the mother (11). The association of NEOC with concentrations of sex steroid hormones during the last pregnancy preceding the index diagnosis was explored in a case–control study, nested within the large, nation-wide Finnish Maternity Cohort (FMC). Early pregnancy (6–21 gestational weeks) concentrations of testosterone, androstenedione, 17-OH-progesterone (the precursor hormone for ovarian and adrenal synthesis of androgens; refs. 18, 19), progesterone, estradiol and sex hormone binding globulin (SHBG) were measured. To our knowledge, this is the first epidemiologic investigation to directly assess the associations of endogenous sex steroid hormones with maternal risk of SCST and GCT.

Materials and Methods

Study population

The FMC is the world’s largest biorepository of serum specimens from pregnant women. It was established in 1983 with the purpose of preserving for research serum samples drawn in the latter part of the first trimester, or the early weeks of the second trimester, from pregnant women during mandatory testing for systemic infections (20, 21). After testing, leftover sera are put away for long-term storage at \(-25^\circ\)C in a central repository. The repository contains more than 1.6 million samples donated by over 850,000 women, from more than 98% of all pregnancies in the country.

Selection of cases and controls

The design was a case–control study nested within the FMC. Eligible women were FMC members who donated a blood sample between gestational weeks 6 and 21 of a pregnancy which resulted in a singleton birth, and who were free of any invasive (except nonmelanoma skin), or borderline ovarian cancer at the time of blood donation. Eligible cases were identified through a linkage with the Finnish Cancer Registry (FCR). The FCR started recording cancer cases in 1953. The registry covers the entire territory of Finland, which now comprises a population of about 5.4 million, almost entirely Caucasian. Reporting of new cancer cases is mandatory since 1961, and the coverage of the FCR is virtually complete with no losses to follow-up (22). Cases were women diagnosed with primary NEOC after recruitment into the cohort until February 2007 with information on gestational age at blood donation. If a case subject had more than one eligible sample preceding the index diagnosis, the one donated closest in time to the date of diagnosis was selected for the study. With one exception, the index sample was from the last pregnancy preceding the cancer diagnosis. A total of 85 potentially eligible cases were identified. Lists with up to 10 potentially eligible controls per each case, matched on age (± 6 months), date (± 3 months), and parity at index pregnancy were initially drawn.

A record linkage with the Finnish Population Registry led to the exclusion of 8 cases (5 whose pregnancy did not end with a child birth and 3 multiple births). A linkage of the working file with detailed FMC files was conducted to verify information on gestational age at blood donation and to check for sample availability. Twelve cases were further excluded: 2 cases who donated a blood sample outside gestational weeks 6 to 21, and 10 cases with no available sample. The same exclusion criteria were applied to the pool of controls. Three controls among those fully eligible per each case were selected at random. Three cases with no eligible controls were further excluded and for 12 cases, only two (\(n = 10\)) or one (\(n = 2\)) eligible control was available. For 9 controls, a sample from the last but one pregnancy preceding index date was available. In total, 62 cases of NEOC and 171 controls (41 cases and 113 controls for SCST; 21 cases and 58 controls for GCT) were included in the study. Further data about maternal and child characteristics during index birth were obtained from a linkage with the Finnish Birth Registry (23). Information on invasive breast and ovarian cancers diagnosed among the first-degree relatives of the study subjects was obtained through separate linkages with the Population and Cancer Registries.

Laboratory analyses

Hormonal analyses were performed at the Clinical Chemistry Laboratory of Umeå University Hospital, Umeå, Sweden. The technicians performing the assays were unaware of the case, control, or quality control status of the specimens. Serum specimens of individually matched case and control subjects were always included in the same laboratory run. In addition to routine laboratory quality controls, a pool of serum from the cohort was created at the beginning of the study and 2 aliquots, undistinguishable from the test samples were inserted in each laboratory run. Sex steroids were quantified by the LC/MS on an Applied Biosystems API4000 triple stage quadrupole mass spectrometer, which has demonstrated good laboratory performances as supported by other studies (24–27). Laboratory quality controls most closely corresponding to the levels observed in the population: 0.1 ng/mL for testosterone, 5.0 ng/mL for androstenedione, 5.0 ng/mL for 17-OH-progesterone, 75.0 ng/mL for progesterone, and 5.0 ng/mL for estradiol, showed inter-run coefficients of variation (CV) of 14.6%, 5.3%, 5.0%, 5.0%, and 8.3%, respectively. Inter- and intrarun CV based on the blinded pool of quality controls were 3.6% and 7.8% for testosterone, 4.0% and 8.3% for androstenedione, 5.4% and 8.1% for 17-OH-progesterone, 3.5% and 7.0% for progesterone, and 5.5% and 6.3% for estradiol. SHBG was quantified with solid-phase competitive chemiluminescence assays on Immulite 2000 Siemens analyzer. The inter-run CV based on laboratory quality controls with concentrations of 41 nmol/L was 1.5%. Because of low sample volume, SHBG measurements were possible only 25 SCST cases and 43 matched controls, and 13 GCT cases and 27 matched controls.
controls. Bioavailable fractions of testosterone and estradiol concentrations were calculated by mass action models based on concentrations of total hormones in blood and their affinity constants for albumin and SHBG (28). No outliers, defined as concentrations exceeding 3 times the interquartile range, for any of the hormones were identified.

**Statistical analysis**

Prior to analysis, all original hormone values were log<sub>2</sub> transformed to normalize their distributions. Hormone concentrations varied linearly with gestational age (Fig. 1) and all statistical analyses were adjusted for gestational age.

Pearson partial correlation coefficients were used to relate hormone concentrations to specific characteristics of interest (e.g., maternal age at sampling (last birth)). Mixed-effect models were used to compare mean hormone concentrations in cases and controls. The conditional logistic regression models (appropriate for the individually matched design) were used to compare differences between cases and controls and to calculate ORs and corresponding 95% CIs for SCST and GCT. For the hormonal variables, ORs were calculated for a unit change of log<sub>2</sub>-transformed concentrations, which corresponds to doubling of the concentrations. To ensure that study results were not influenced by the presence of yet undiagnosed, but hormonally active tumor, sensitivity analyses excluding women diagnosed within 2, 4, and 6 years after blood donation were conducted. For subjects with SHBG measurements, bioavailable fractions of testosterone and estradiol were also related to risk. Further subgroup analyses by ages at sampling (<30 vs. ≥30 years) and cancer diagnosis (below and above 40 years), limited to multiparous women, to those who donated an eligible sample during the last pregnancy preceding the index date, or with borderline tumors for SCST were also performed. Tests of homogeneity between the ORs in different subgroups were based on χ² statistics, calculated as the deviations of logistic regression coefficients observed in each of the subgroups, relative to the overall regression coefficient (29). The effect of potential confounders (e.g., maternal age at first birth, family history of breast/ovarian cancers, maternal smoking, the child’s sex, birth length and weight) was evaluated and variables that changed point estimates by more than 5% for two or more hormones were retained in the final models. The effect of adjustment for hormone concentrations included adjustment of testosterone models for androstenedione (and vice versa) and adjustment of androgen and progesterone models for 17-OH-progesterone (and vice versa) was also explored. All tests of statistical significance were 2 sided and the ORs were considered significant if the values of P < 0.05.

The study was approved by the ethical committees of the National Institute for Health and Welfare, Finland; University of Umeå, Sweden; and German Cancer Research Center, Germany.

**Results**

SCST and GCT cases and their respective control subjects were comparable in most pregnancy, maternal, and child characteristics (Table 1). The median age at diagnosis was 39 years (range: 23.1–50.0) for SCST and 35 years (range: 21.1–51.4) for GCT. The majority of SCST were borderline tumors (33 cases, 80%), whereas most of GCT were invasive cancer (18 cases, 86%). The vast majority of SCST (85%, 35 cases) were granulosa cell tumors. The lag time between blood donation and diagnosis was shorter for GCT than for SCST (4.1 vs. 6.8 years, respectively).

Correlations of sex steroids hormones with each other and with gestational age and maternal age at sampling in the all control subjects (N = 171) are presented in Table 2. The strongest correlations were observed between the 2 androgens (r = 0.87) which were also directly correlated with 17-OH-progesterone (r = 0.54 and 0.63 for testosterone and androstenedione, respectively). Progesterone was weakly positively correlated with androgens (r = 0.21 and 0.26 for testosterone and androstenedione, respectively) and moderately with 17-OH-progesterone (r = 0.50). Interestingly, in the case group of women with SCST weak inverse correlations of progesterone with androgens were observed (r = −0.18 and r = −0.10) and the correlation with 17-OH-progesterone was less pronounced (r = 0.20). Estradiol was moderately positively correlated with other sex steroids in the controls (correlation coefficients ranging from 0.29 to 0.55), but in the SCST cases, only very weak correlations of estradiol with androgens and 17-OH-progesterone were observed (ranging from −0.06 to 0.13). There was no correlation of maternal age with any of the studied hormones among controls.

Testosterone, androstenedione, and 17-OH-progesterone concentrations were significantly higher in SCST cases than in their controls, but no other significant differences in hormone levels between SCST or GCT cases and their controls were observed (Table 1). SHBG concentrations were marginally higher in SCST cases than in their controls (189 vs. 162 nmol/L; P = 0.08, with only 25 cases and 43 controls). Correspondingly, in conditional regression analyses (Table 3), doubling of androgen and 17-OH-progesterone concentrations were associated with about 2-fold increase in risk of SCST. Adjustment for maternal age at first birth, family history of breast/ovarian cancers, maternal smoking, and child sex increased risk estimates, with maternal age at first birth having the greatest impact (about 9% increase of androgen and 5% increase for 17-OH-progesterone estimates). The associations remained largely unchanged after excluding women with 2-, 4-, or 6-year lag time between blood donation and cancer diagnosis (Table 3). Doubling of SHBG, bioavailable fractions of testosterone and estradiol were not statistically significantly associated with risk of SCST (OR and 95% CI of 1.88 (0.70–5.04), 1.18 (0.52–2.64), and 0.97 (0.31–3.02), respectively).
Sex Steroids in Pregnancy and Maternal Risk of Non-epithelial Ovarian Cancer

Figure 1. Scatterplot of log2-scale testosterone (A), androstenedione (B), 17-OH-progesterone(C), progesterone (D), estradiol (E), and SHBG (F) concentrations (controls combined) by gestational age. The solid line shows the progression of hormone concentrations during pregnancy, estimated by linear regression.
Table 1. Distribution of characteristics of NEOC cases and their matched controls, median (min, max), or n (%) from the FMC, 1983–2007

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>SCST</th>
<th>GCT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cases (41)</td>
<td>Controls (113)</td>
</tr>
<tr>
<td>Age at index (last) birth, a y</td>
<td>30.8 (22.2–40.0)</td>
<td>30.9 (21.7–40.9)</td>
</tr>
<tr>
<td>Parity at index pregnancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>6 (15%)</td>
<td>18 (16%)</td>
</tr>
<tr>
<td>2</td>
<td>17 (41%)</td>
<td>49 (43%)</td>
</tr>
<tr>
<td>3+</td>
<td>18 (44%)</td>
<td>46 (41%)</td>
</tr>
<tr>
<td>Age at first birth, y</td>
<td>25.8 (18.6–40.5)</td>
<td>25.3 (16.4–41.4)</td>
</tr>
<tr>
<td>Gestational age, wk</td>
<td>11 (7–16)</td>
<td>11 (6–20)</td>
</tr>
<tr>
<td>Age at diagnosis, y</td>
<td>39.0 (23.1–50.0)</td>
<td>–</td>
</tr>
<tr>
<td>Lag time, y</td>
<td>6.8 (0.1–19.4)</td>
<td>–</td>
</tr>
<tr>
<td>Cancer type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive</td>
<td>8 (20%)</td>
<td>–</td>
</tr>
<tr>
<td>Borderline</td>
<td>33 (80%)</td>
<td>–</td>
</tr>
<tr>
<td>Family history of ovary cancer</td>
<td>0 (0%)</td>
<td>1 (1%)</td>
</tr>
<tr>
<td>Family history of breast cancer</td>
<td>1 (2%)</td>
<td>1 (1%)</td>
</tr>
<tr>
<td>Smoking (yes)</td>
<td>4 (10%)</td>
<td>17 (16%)</td>
</tr>
<tr>
<td>Child sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>18 (45%)</td>
<td>62 (56%)</td>
</tr>
<tr>
<td>Female</td>
<td>22 (55%)</td>
<td>48 (44%)</td>
</tr>
<tr>
<td>Child birth weight, g</td>
<td>3,535</td>
<td>3,560</td>
</tr>
<tr>
<td></td>
<td>(2,080–4,650)</td>
<td>(1,900–4,670)</td>
</tr>
<tr>
<td>Child birth length, cm</td>
<td>50 (42–55)</td>
<td>50 (43–57)</td>
</tr>
<tr>
<td>Hormonesa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testosterone, ng/mL</td>
<td>1.09 (0.95–1.24)</td>
<td>0.86 (0.79–0.93)</td>
</tr>
<tr>
<td>Androstenedione, ng/mL</td>
<td>2.36 (2.08–2.67)</td>
<td>1.96 (1.81–2.11)</td>
</tr>
<tr>
<td>17-OH-progesterone, ng/mL</td>
<td>2.86 (2.55–3.21)</td>
<td>2.42 (2.23–2.62)</td>
</tr>
<tr>
<td>Progesterone, ng/mL</td>
<td>22.2 (20.4–24.2)</td>
<td>23.6 (22.4–25.0)</td>
</tr>
<tr>
<td>Estradiol, ng/mL</td>
<td>2.05 (1.79–2.34)</td>
<td>2.00 (1.84–2.18)</td>
</tr>
</tbody>
</table>

NOTE: Conditional logistic regression models were used to compare differences between cases and controls; mixed-effect models were used to compare mean hormone concentrations in cases and controls.

aSamples not from the last pregnancy preceding cancer diagnosis (3 SCST controls, 1 GCT case, and 6 GCT controls).

Geometric means and (10th, 90th) percentile of hormone concentrations (adjustment for gestational age and maternal age).

Subgroup analyses by ages at sampling and diagnosis indicated somewhat stronger associations in women who were diagnosed before age 40 than after that age, but the heterogeneity tests reached statistical significance only for the effect of doubling of 17-OH-progesterone. In spite of statistical significance, however, these results should be interpreted with some caution as the heterogeneity tests were based on small numbers of subjects and were sensitive to selection of cutoff points. Analyses limited to multiparous women (33 cases, 80%) yielded similar results to those reported overall. Adjustment of testosterone models for androstenedione did not alter the magnitude of the risk estimates, whereas adjustment of androstenedione models for testosterone completely abolished the association of androstenedione with risk (data not shown). Adjustment of androgen models for 17-OH-progesterone or of 17-OH-progesterone models for androgens resulted in substantial reduction of risk estimates (data not shown).

Sex steroids showed were not associated with maternal risk of GCT (Table 4). SHBG concentrations were associated with higher risk (not statistically significant); however, only 13 case-control sets were included in this analysis, and the CI were large [OR and 95% CI of 2.01 (0.39–10.27)]. Analyses excluding case-control sets with lag time to diagnosis of 2, 4, and 6 years and analyses limited to multiparous women (15 cases) or invasive tumors (18 cases, 86%) were similarly unremarkable.

Discussion

This is the first prospective study to provide direct epidemiologic evidence that elevated blood levels of sex steroid hormones during pregnancy, androgens in
Table 2. Pearson partial correlations between hormones, maternal age at index pregnancy, and gestational day in all control subjects (n = 171) from the FMC, 1983–2007

<table>
<thead>
<tr>
<th>Hormones</th>
<th>Testosterone</th>
<th>Androstenedione</th>
<th>17-OH-progesterone</th>
<th>Progesterone</th>
<th>Estradiol</th>
<th>SHBG&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone, ng/mL</td>
<td>0.38 (&lt;i&gt;P&lt;/i&gt; = 0.002)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Androstenedione, ng/mL</td>
<td>0.26 (&lt;i&gt;P&lt;/i&gt; = 0.01)</td>
<td>0.26 (&lt;i&gt;P&lt;/i&gt; = 0.01)</td>
<td>0.50 (&lt;i&gt;P&lt;/i&gt; &lt; 0.0001)</td>
<td>0.37 (&lt;i&gt;P&lt;/i&gt; = 0.0002)</td>
<td>0.38 (&lt;i&gt;P&lt;/i&gt; = 0.002)</td>
<td></td>
</tr>
<tr>
<td>17-OH-progesterone, ng/mL</td>
<td>0.54 (&lt;i&gt;P&lt;/i&gt; &lt; 0.0001)</td>
<td>0.63 (&lt;i&gt;P&lt;/i&gt; &lt; 0.0001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Progesterone, ng/mL</td>
<td>0.21 (&lt;i&gt;P&lt;/i&gt; = 0.01)</td>
<td>0.26 (&lt;i&gt;P&lt;/i&gt; = 0.001)</td>
<td>0.50 (&lt;i&gt;P&lt;/i&gt; &lt; 0.0001)</td>
<td>0.37 (&lt;i&gt;P&lt;/i&gt; = 0.0002)</td>
<td>0.38 (&lt;i&gt;P&lt;/i&gt; = 0.002)</td>
<td></td>
</tr>
<tr>
<td>Estradiol, ng/mL</td>
<td>0.55 (&lt;i&gt;P&lt;/i&gt; &lt; 0.0001)</td>
<td>0.49 (&lt;i&gt;P&lt;/i&gt; &lt; 0.0001)</td>
<td>0.29 (&lt;i&gt;P&lt;/i&gt; = 0.0001)</td>
<td>0.50 (&lt;i&gt;P&lt;/i&gt; &lt; 0.0001)</td>
<td>0.67 (&lt;i&gt;P&lt;/i&gt; &lt; 0.0001)</td>
<td></td>
</tr>
<tr>
<td>Maternal age at sampling, y</td>
<td>0.05 (&lt;i&gt;P&lt;/i&gt; = 0.56)</td>
<td>−0.02 (&lt;i&gt;P&lt;/i&gt; = 0.76)</td>
<td>0.03 (&lt;i&gt;P&lt;/i&gt; = 0.66)</td>
<td>0.06 (&lt;i&gt;P&lt;/i&gt; = 0.45)</td>
<td>−0.003 (&lt;i&gt;P&lt;/i&gt; = 0.97)</td>
<td>−0.002 (&lt;i&gt;P&lt;/i&gt; = 0.98)</td>
</tr>
<tr>
<td>Gestational age, d</td>
<td>−0.12 (&lt;i&gt;P&lt;/i&gt; = 0.12)</td>
<td>−0.25 (&lt;i&gt;P&lt;/i&gt; = 0.001)</td>
<td>−0.32 (&lt;i&gt;P&lt;/i&gt; &lt; 0.0001)</td>
<td>0.51 (&lt;i&gt;P&lt;/i&gt; &lt; 0.0001)</td>
<td>0.67 (&lt;i&gt;P&lt;/i&gt; &lt; 0.0001)</td>
<td>0.63 (&lt;i&gt;P&lt;/i&gt; &lt; 0.0001)</td>
</tr>
</tbody>
</table>

NOTE: All correlations (except those with gestational day) were adjusted for gestational age.

<sup>a</sup>Data available for 95 subjects only.
Table 3. ORs and 95% CIs for ovarian SCST associated with doubling of hormone concentrations from the FMC, 1983–2007

<table>
<thead>
<tr>
<th></th>
<th>Testosterone</th>
<th>Androstenedione</th>
<th>17-OH-progesterone</th>
<th>Progesterone</th>
<th>Estradiol</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OR (95% CI)</strong></td>
<td>P</td>
<td>OR (95% CI)</td>
<td>P</td>
<td>OR (95% CI)</td>
<td>P</td>
</tr>
<tr>
<td><strong>SCST (41/113)</strong></td>
<td>1.90 (1.13–3.21)</td>
<td>0.02</td>
<td>1.76 (1.03–3.03)</td>
<td>0.04</td>
<td>2.07 (1.07–4.02)</td>
</tr>
<tr>
<td><strong>Multivariate modela</strong></td>
<td>2.16 (1.25–3.74)</td>
<td>0.006</td>
<td>2.16 (1.20–3.87)</td>
<td>0.01</td>
<td>2.62 (1.27–5.38)</td>
</tr>
<tr>
<td><strong>Sensitivity analyses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lag time ≥ 2 y (34/91)</td>
<td>2.03 (1.13–3.64)</td>
<td>0.02</td>
<td>1.85 (0.98–3.48)</td>
<td>0.06</td>
<td>1.96 (0.90–4.28)</td>
</tr>
<tr>
<td>Lag time ≥ 4 y (31/18)</td>
<td>2.30 (1.17–4.49)</td>
<td>0.02</td>
<td>1.99 (0.98–4.08)</td>
<td>0.06</td>
<td>2.53 (1.04–6.14)</td>
</tr>
<tr>
<td>Lag time ≥ 6 y (23/63)</td>
<td>3.41 (1.43–8.16)</td>
<td>0.01</td>
<td>2.54 (1.06–6.10)</td>
<td>0.04</td>
<td>1.84 (0.67–5.06)</td>
</tr>
<tr>
<td>Multiparous women (35/95)</td>
<td>2.28 (1.26–4.10)</td>
<td>0.01</td>
<td>2.17 (1.18–4.00)</td>
<td>0.01</td>
<td>2.49 (1.11–5.56)</td>
</tr>
<tr>
<td>Borderline tumors (33/96)</td>
<td>2.01 (1.09–3.72)</td>
<td>0.03</td>
<td>2.06 (1.09–3.88)</td>
<td>0.03</td>
<td>2.58 (1.16–5.70)</td>
</tr>
<tr>
<td><strong>Subgroup analyses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at sampling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30 y (15/40)</td>
<td>3.21 (0.86–11.95)</td>
<td>0.08</td>
<td>2.09 (0.54–8.07)</td>
<td>0.29</td>
<td>4.77 (0.86–26.33)</td>
</tr>
<tr>
<td>≥30 y (26/73)</td>
<td>1.80 (0.92–3.52)</td>
<td>0.09</td>
<td>1.89 (0.95–3.76)</td>
<td>0.07</td>
<td>2.01 (0.88–4.57)</td>
</tr>
<tr>
<td>Age at diagnosisa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;40 y (24/65)</td>
<td>2.91 (1.30–6.50)</td>
<td>0.01</td>
<td>3.14 (1.30–7.57)</td>
<td>0.01</td>
<td>7.68 (1.68–35.13)</td>
</tr>
<tr>
<td>≥40 y (17/48)</td>
<td>1.45 (0.64–3.26)</td>
<td>0.37</td>
<td>1.22 (0.51–2.93)</td>
<td>0.66</td>
<td>1.00 (0.35–3.28)</td>
</tr>
</tbody>
</table>

NOTE: Adjustments for gestational age, maternal age at first birth, family history of breast/ovarian cancers, maternal smoking, and child sex.

aThe heterogeneity tests reached statistical significance only for 17-OH-progesterone (P = 0.03) by age at diagnosis, less than 40 versus 40 years or greater.
Table 4. ORs and 95% CIs for ovarian GCT associated with doubling of hormone concentrations from the FMC, 1983–2007

<table>
<thead>
<tr>
<th>Testosterone</th>
<th>Androstenedione</th>
<th>17-OH-progesterone</th>
<th>Progesterone</th>
<th>Estradiol</th>
</tr>
</thead>
<tbody>
<tr>
<td>OR (95% CI)</td>
<td>P</td>
<td>OR (95% CI)</td>
<td>P</td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td>GCT (21/58)</td>
<td>1.05 (0.54–2.08)</td>
<td>0.88</td>
<td>1.19 (0.54–2.65)</td>
<td>0.66</td>
</tr>
</tbody>
</table>

**NOTE:** None of the heterogeneity tests reached statistical significance and adjustment for gestational age, maternal age at first birth, family history of breast/ovarian cancers, maternal smoking, and child sex.

Sensitivity analyses

<table>
<thead>
<tr>
<th>Lag time</th>
<th>OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 y (16/45)</td>
<td>0.82 (0.34–1.98)</td>
<td>0.66</td>
</tr>
<tr>
<td>4 y (9/28)</td>
<td>0.60 (0.15–2.44)</td>
<td>0.47</td>
</tr>
<tr>
<td>6 y (9/28)</td>
<td>0.56 (0.13–2.36)</td>
<td>0.43</td>
</tr>
</tbody>
</table>

**NOTE:** None of the heterogeneity tests reached statistical significance and adjustment for gestational age, maternal age at first birth, family history of breast/ovarian cancers, maternal smoking, and child sex.
particular, may be related to an increased risk of developing SCST. Doubling of testosterone, androstenedione, and 17-OH-progesterone (the precursor hormone for androgen synthesis) during the early part of the last pregnancy leading to child birth and preceding cancer diagnosis was associated with an approximately 2-fold greater risk of SCST. In contrast, none of the studied steroid hormones showed any association with risk of GCT.

Changes of sex steroids throughout pregnancy are summarized as below. Concentrations of testosterone are relatively stable throughout pregnancy, as demonstrated by longitudinal studies (30, 31). One longitudinal study (31) shows that total testosterone levels remain relatively stable till the third trimester and increase 62% from 6th to 34th week of gestation, and the other longitudinal study (30) reports that total testosterone increases approximately 29% from 5th to 40th week of gestation. The free testosterone levels are within the range of nonpregnant women and gradually increase during the latter parts of pregnancy (31, 32). Androstenedione levels only slightly increase throughout pregnancy in the longitudinal studies (30, 31, 33). 17-OH-progesterone levels reach their peak during the fifth to sixth week of pregnancy and then gradually decrease thereafter, but increase again during the latter parts of pregnancy (30, 34). There are small variations in progesterone levels, similar to pre-pregnancy state (luteal phase of the menstrual cycle), from third to thirteenth week of gestation, and progesterone levels increase significantly thereafter (30, 34, 35). Estradiol levels rise steadily from third to thirteenth week of gestation (by eighth week of gestation its levels are above the range found during menstrual cycle) and then gradually increase thereafter (34–37). SHBG levels increase rapidly during the first half of pregnancy (till 25th week of gestation), then remained relatively constant until delivery (30, 31). All studied hormones levels at 1 year postpartum drop down to below the first trimester values, similar to the pre-pregnancy state (31, 33).

The 2-fold higher risk of SCST associated with elevated prediagnostic androgen concentrations is consistent with results from animal studies. Experiments in rodents have demonstrated that androgens may be involved in ovarian cancer induction, though a long induction period may be required (38–42). In particular, testosterone and dehydroepiandrosterone strongly promote carcinogenesis of spontaneous ovarian granulosa cell tumors (the predominant histologic subtype in this study) in SWXJ-9 strain mice (38) and continuous administration with testoster- one shortly after birth induced theca-cell ovarian tumors (also belonging to SCST) in the rat (39). Therefore, it is plausible that androgens are involved in the pathogenesis of SCST in humans.

The elevations in androgens and 17-OH-progesterone in the SCST case subjects are likely to be of maternal origin. Although the placenta produces androstenedione and testosterone from fetal precursors, these are rapidly converted to estrogens due to its potent aromatase capacity (43). 17-OH-progesterone is considered to reflect activities of corpus luteum, indicating ovarian steroidogenesis, particularly during the first trimester (36). Nevertheless, maternal 17-OH-progesterone during the latter parts of pregnancy could be derived from maternal and fetal adrenal glands as well as from the placenta sources (44), as the placenta does not secrete 17-OH-progesterone until 32 week of pregnancy (43, 45) due to the lack of 17α-hydrolase activity. In contrast, the concentrations of progesterone and estradiol, which are predominantly of placental origin in the phase of pregnancy during which study samples were collected (45), were similar in case and control subjects and were not related to risk of SCST. The divergent correlations of androgens and 17-OH-progesterone with estradiol and progesterone concentrations in the SCST cases and in the control group further underscores the possibility of differences in sex steroid hormones metabolism between cases and controls.

Androgens measured during early pregnancy are likely to reflect pre-pregnancy exposure to the hormone because concentrations of androgens (testosterone and androstenedione) during early pregnancy and in the nonpregnant state are relatively similar (30, 31). It is plausible to assume that women from general population, having normal pre-pregnancy androgens, continue to have normal androgens during early pregnancy. Similarly, this assumption is likely generalizable to women with polycystic ovary syndrome (PCOS) as evidence (37, 43) has demonstrated that pregnant women with PCOS, having elevated pre-pregnancy androgens, continue to maintain higher androgens also during pregnancy, compared with normal pregnant women with normal androgen levels. Therefore, the observed increase in risk of SCST associated with doubling of testosterone in our study may be applicable also to the effect of elevated androgens/ altered maternal androgen metabolism in the nonpregnant state.

The major strength of our study is its prospective design, which largely avoids selection and inverse causation biases which plague studies of a classical case–control design. Case and control subjects were tightly matched for age at sampling (last birth), parity at the index pregnancy, and date of sampling, allowing careful control for these important sources of potential confounding. SCST develop from the theca and granulosa cells, which are the major site of steroid hormones synthesis in the ovary (4, 46), and these tumors are often hormonally active (5, 47). To reduce the possibility that the observed associations with risk of SCST were influenced by hormonal secretion by a growing, but still undiagnosed tumor we limited the analyses to women whose samples were donated 2, 4 and 6 years prior to their cancer diagnosis. For testosterone, the more potent androgen, risk estimates remained strong and statistically significant, whereas those for androstenedione were slightly reduced and became of borderline significance. Thus, it is unlikely that the observed associations in our study were due to reverse causation bias.
The very large overall size of Finnish Maternity Cohort \( (N \approx 850,000) \) made it possible to study the hormonal determinants of non-epithelial ovarian tumors, which are rare forms of cancer; although, the very small numbers of cases, particularly for GCT, was insufficient to detect moderate or weak hormone-risk associations. A limitation of our study is that no data on maternal pre-pregnancy hyperadrogenism/testosterone concentrations were available and the lack of sufficient sample for analyses of SHBG in all subjects. Study samples had been stored at relatively high temperature \((-25^\circ \text{C})\), but we observed no correlations of hormone levels with time in storage and their concentrations varied with gestational age as expected, as also shown previously \((48)\).

It is not feasible in the study design to select controls matched to cases on gestational age, even in much larger cohorts and will pose unreasonable, severe restraints on control selection. Therefore, the only alternative is to adjust for gestational age in the phase of data analysis to minimize the intra-person variability in sex steroids levels during pregnancy. One approach is adjusted for a linear term of gestational age, and the other is calculating residual values by the local linear regression \((49)\). We adopt the former approach in the article due to the following 4 reasons. First, concentrations of all studied hormone varied linearly with gestational age (Fig. 1). Second, the same approach has been extensively used in various epidemiologic studies \((50–53)\). Third, in fact the former approach provides more straightforward interpretation in comparison with the presentation of residual values by the local linear regression, as the latter approach is required to calculate the difference (residual) between the assay value and the estimated mean hormone value determined for the day of gestation on which the blood sample was donated. Finally, results obtained by both approaches give almost identical results. It is also possible that hormones levels adjusted for gestational age could be subject to measurement error. However the intra-person variability in biomarker levels from a single measurement is unlikely to be differential with respect to cases and controls and would most likely lead to an underestimation of the effect estimates, as supported by other studies \((54–57)\).

Another relative limitation of the study might be that only a single blood sample was obtained for each pregnant woman. A single measurement for endogenous sex steroids in premenopausal women is suggested to reliably estimate average levels for serum androgen and SHBG over a 1- to 3-year period \((58, 59, 55, 60, 61)\). To our knowledge, so far no study on the reproducibility of a single measurement for endogenous sex steroids in pregnant women has been reported and little is known about the intra-person variability in sex steroids during pregnancy. Although a lot of work has been done in relation to Down syndrome markers, so far only 3 studies \((62–64)\), after exhausting literature searches, on the correlations between sex steroids levels during different period of the same pregnancy have been identified. Nevertheless, it is plausible to conclude that sex steroids hormones track during pregnancy as there are moderate-to-strong correlations \((more than 0.40)\) between concentrations of sex steroids during the different period \((62–64)\) of the same pregnancy. Firstly, correlations between the first and second trimester in both Caucasian women and Chinese women were strong for testosterone \((0.83 \text{ for Boston and 0.62 for Shanghai})\), SHBG \((0.85 \text{ for Boston and 0.67 for Shanghai})\), and estradiol \((0.72 \text{ for Boston and 0.61 for Shanghai}, \text{and modest for progesterone (0.45 for Boston and 0.39 for Shanghai); ref. 62})\). Secondly, correlations between the first and third trimester in white women were \(0.53 \text{ for testosterone, 0.23 for SHBG, and 0.25 for estradiol; whereas in black women were higher, 0.67 for testosterone, 0.43 for SHBG, and 0.35 for estradiol (63)}\). Thirdly, correlations between the second and third trimester were \(0.78 \text{ for estradiol and 0.60 for total estrogen (64)}\). In addition, strong correlations during successive pregnancies of the same women for estrogen have been reported, for example, pregnancy estradiol, measured between eighth and seventeenth of gestational weeks, were strongly correlated in successive pregnancies of the same women \((0.78 \text{ for total estradiol and 0.73 for free estradiol; ref. 65})\). It is plausible to assume that the correlations of hormone levels measured within the same pregnancy is most likely higher than those correlations of hormone levels measured in successive pregnancies.

Taken together, a single measurement for androgens (testosterone in particular) during early pregnancy can reliably represent cumulative exposure to the hormone as strong correlations during the different period of the same pregnancy for testosterone have been reported, for example, correlations between the first and second trimester were \(0.83 \text{ for Caucasian women in Boston and 0.62 for Chinese women in Shanghai (62)}\), and correlations between the first and third trimester were \(0.67 \text{ in black women and 0.53 in white women (63)}\). In addition, concentrations of androgens are relatively stable throughout pregnancy \((30, 31, 33)\), and androgens levels during early pregnancy and in the nonpregnant state are also relatively similar \((30, 31)\). The samples of the FMC were donated around the first trimester, between the sixth and twenty-first weeks of gestation, which is likely to be the most relevant period for the exposure to early pregnancy androgens (testosterone in particular), also reflecting pre-pregnancy exposure to the hormone.

A completion of the first full-term pregnancy may induce substantial alternations in a woman’s hormonal milieu as most studies have shown that in pregnant state, parous women have lower concentrations of a number of hormones, including estrogens and androgens \((64, 66–69)\), compared with nulliparous women. Effects of pregnancy on hormone levels may sustain in the nonpregnant state, for example, before and after menopause. Although, some studies report that nulliparous women had similar (higher trend, but not statistically significant) androgens (testosterone and androstenedione) levels, in comparison with
parous women, both in the pre-menopausal (70, 71) and postmenopausal women (72–74). Most studies support of reductions in concentrations of sex steroids after the first full-term pregnancy both in the pre-menopausal women for androgens [DHEA and DHEA sulfate (DHEAS); ref. 75], progesterone (71), and estrogens (free estradiol; ref. 76), and also in the postmenopausal women for androgens (testosterone; ref. 77), and estrogens (free estradiol; ref. 78) and estrone sulfate (79).

Therefore, the effect of pregnancy on maternal risk of NEOC is most likely to be the result of the cumulative long-term exposure of androgens (testosterone in particular) throughout a woman’s life cycle till cancer diagnosis, by promoting carcinogenesis of spontaneous ovarian granulosa cell tumors or inducing theca-cell ovarian tumors, as animal studies (38–42) has demonstrated that androgens may be involved in ovarian cancer induction after a long induction period.

In summary, this study is the first prospective epidemiologic investigation providing initial direct evidence that elevated androgens and testosterone in particular, play an important role in the pathogenesis of SCST long before the clinical onset of the disease. Our data suggest that SCST and GCT have distinct hormonal risk profiles, possibly reflecting differences in their pathogenesis. Our study may note a particular need for larger confirmatory investigations on sex steroids and NEOC.

Disclosure of Potential Conflict of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors are indebted to Yelena Afanasyeva, Pirjo Kontiokari, Annika Uimonen, and Sara Kuusiniemi for their excellent technical assistance in the conduct of the study.

Grant Support

This research was supported by the National Cancer Institute at the NIH (R01-CA120061). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 16, 2010; revised November 26, 2010; accepted December 2, 2010; published OnlineFirst December 21, 2010.

References


Circulating Sex Steroids during Pregnancy and Maternal Risk of Non-epithelial Ovarian Cancer


Updated version
Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-10-0857

Cited articles
This article cites 72 articles, 10 of which you can access for free at:
http://cebp.aacrjournals.org/content/20/2/324.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.